4//SEC Filing
Kirk Sigurd 4
Accession 0001209191-08-067596
CIK 0000010081other
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 7:01 PM ET
Size
24.8 KB
Accession
0001209191-08-067596
Insider Transaction Report
Form 4
Kirk Sigurd
Sr VP Finance & Corp Controlle
Transactions
- Disposition to Issuer
Stock Appreciation Rights
2008-12-23−6,000→ 0 totalExercise: $46.99Exp: 2015-07-27→ Common Stock (6,000 underlying) - Disposition to Issuer
Stock Options
2008-12-23−1,500→ 0 totalExercise: $44.63Exp: 2013-08-04→ Common Stock (1,500 underlying) - Disposition to Issuer
Stock Appreciation Rights
2008-12-23−15,000→ 0 totalExercise: $48.80From: 2008-11-11Exp: 2016-07-26→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Appreciation Rights
2008-12-23−12,000→ 0 totalExercise: $49.49From: 2008-11-11Exp: 2017-03-07→ Common Stock (12,000 underlying) - Disposition to Issuer
Common Stock
2008-12-23−1,064→ 0 total - Disposition to Issuer
Stock Options
2008-12-23−3,000→ 0 totalExercise: $35.01Exp: 2014-08-04→ Common Stock (3,000 underlying) - Disposition to Issuer
Stock Appreciation Rights
2008-12-23−30,000→ 0 totalExercise: $49.22From: 2008-11-11Exp: 2018-03-04→ Common Stock (30,000 underlying)
Footnotes (8)
- [F1]Disposed of pursuant to a merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 667 shares of Teva Common Stock having a market value of $41.82 per share on the effective date of the merger and cash in the amount of $42,453.60.
- [F2]Option vested equally over a 3 year period from grant date
- [F3]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $32,800.05, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $44.6333 per share.
- [F4]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $94,470, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $35.01 per share.
- [F5]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $117,060, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $46.99 per share.
- [F6]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $265,500, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $48.80 per share.
- [F7]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $204,120, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.49 per share.
- [F8]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $518,400, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.22 per share.
Issuer
BARR PHARMACEUTICALS INC
CIK 0000010081
Entity typeother
Related Parties
1- filerCIK 0001429125
Filing Metadata
- Form type
- 4
- Filed
- Dec 28, 7:00 PM ET
- Accepted
- Dec 29, 7:01 PM ET
- Size
- 24.8 KB